Novo Nordisk’s Ozempic, Astellas’ Xtandi and Pfizer’s Ibrance are among the 15 drugs that have a new fair maximum price.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...

New Medicare-negotiated prices for 15 widely used medications take effect in 2027, impacting more than 5 million ...

The savings go into effect in 2027 and are expected to save billions for government health program.

The Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those ...

New prices for enrollees will start in 2027 ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...

A new round of Medicare drug price negotiations shows the impact of the Inflation Reduction Act while exposing an ongoing political fight over who deserves credit for lowering drug costs. The Trump ...

The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer. Breast cancer in women is the second most common type of ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...